Search for retatrutide online and one term appears again and again:
It sounds plausible.
Semaglutide is associated with GLP-1 receptor agonism. Tirzepatide adds a second hormonal pathway. Retatrutide activates three receptors.
So “GLP-3” can sound like a convenient shorthand for a third-generation GLP drug.
The problem is that GLP-3 is not what retatrutide is.
There is no GLP-3 receptor involved in retatrutide’s mechanism.
Retatrutide is a GIP, GLP-1, and glucagon receptor triple agonist. Those are three different hormone receptor systems, not three generations or three types of GLP signaling.
Even Eli Lilly, the company developing retatrutide, has addressed the terminology directly and says “triple agonist” is the more appropriate description.
Understanding the difference is useful because the correct name tells researchers something important about how the molecule actually works.
What Does GLP Stand For?
GLP stands for glucagon-like peptide.
The best-known member in metabolic pharmacology is glucagon-like peptide-1, or GLP-1.
GLP-1 is an endogenous peptide hormone produced from the proglucagon precursor.
It interacts with the GLP-1 receptor, abbreviated GLP-1R.
GLP-1 signaling participates in several physiological processes, including:
- glucose-dependent insulin secretion
- regulation of glucagon secretion
- gastric function
- appetite and satiety signaling.
Drugs that selectively activate GLP-1R are therefore called GLP-1 receptor agonists.
That terminology refers to a specific receptor.
It is not a numbering system for generations of metabolic drugs.
Retatrutide Still Activates GLP-1R
GLP-1 signaling is indeed one component of retatrutide’s pharmacology.
But it is only one component.
Retatrutide activates:
GIPR
The glucose-dependent insulinotropic polypeptide receptor.
GLP-1R
The glucagon-like peptide-1 receptor.
GCGR
The glucagon receptor.
Lilly consistently describes the molecule as a GIP, GLP-1, and glucagon triple hormone receptor agonist.
That phrase is longer than “GLP-3,” but it is scientifically meaningful.
It identifies the actual receptors.
There Is No “Third GLP Receptor” in Retatrutide
Calling retatrutide GLP-3 can create the impression that it activates something called GLP-3R.
It does not.
The third receptor is GCGR, the glucagon receptor.
And GIPR is not a GLP receptor either.
A more accurate shorthand would therefore be:
GIP/GLP-1/glucagon triagonist
or:
triple hormone receptor agonist.
The distinction is not merely semantic.
The glucagon receptor introduces biology that is substantially different from GLP-1 receptor signaling.
Why the “GLP-3” Nickname Probably Appeared
The terminology is easy to understand from a consumer perspective.
Modern metabolic drugs can look like a sequence of increasing receptor complexity.
For example:
Semaglutide: GLP-1R agonist
Tirzepatide: GIPR + GLP-1R agonist
Retatrutide: GIPR + GLP-1R + GCGR agonist
That creates an intuitive pattern of:
one target → two targets → three targets.
Calling the third compound “GLP-3” compresses that pattern into a short phrase.
But it sacrifices scientific accuracy.
Retatrutide is not three GLP pathways stacked together.
It adds two different receptor systems to GLP-1R signaling.
Tirzepatide Was Already More Than a GLP-1 Drug
The same distinction becomes clearer when looking at tirzepatide.
Tirzepatide is often grouped with GLP-1 medicines because it activates GLP-1R.
But scientifically, tirzepatide is a dual GIP/GLP-1 receptor agonist.
Its GIP receptor activity is not simply a stronger form of GLP-1 signaling.
It is a separate receptor pathway.
Retatrutide builds on this broader multi-receptor approach by adding glucagon receptor agonism.
So the progression is better described as:
single agonism
to
dual agonism
to
triple agonism
rather than:
GLP-1 → GLP-2 → GLP-3.
What Is GIPR?
GIPR is the receptor for glucose-dependent insulinotropic polypeptide.
GIP is an incretin hormone released in response to nutrient intake.
Its receptor is expressed in several tissues and participates in metabolic signaling, including glucose-dependent insulin responses.
Retatrutide was actually engineered with particularly strong functional potency at the human GIP receptor in laboratory assays.
That fact would be obscured by calling the molecule GLP-3.
The nickname puts GLP-1 at the center of the name even though retatrutide’s pharmacology is intentionally broader.
What Is GCGR?
GCGR is the glucagon receptor.
Glucagon is best known for increasing hepatic glucose production, particularly during fasting or low blood glucose.
But its physiology extends further.
Glucagon receptor signaling also affects:
- hepatic lipid metabolism
- amino-acid metabolism
- nutrient partitioning
- energy expenditure.
This receptor is one of the most scientifically interesting parts of retatrutide’s design.
Preclinical work suggests that GCGR activation can add an energy-expenditure component to the appetite and metabolic effects associated with GIPR and GLP-1R signaling.
That mechanism is one reason retatrutide is not simply another GLP-1 agonist.
Triple Agonism Is the Point
Retatrutide’s scientific identity comes from the interaction of all three receptor pathways.
The molecule was intentionally engineered as a unimolecular polyagonist.
That means one peptide activates several receptors.
The approach differs from combining three separate compounds.
A single peptide provides one pharmacokinetic profile, one molecular structure, and a designed balance of receptor potencies.
That balance is important because retatrutide does not activate each receptor equally.
Structural and functional studies show distinct potency at GIPR, GLP-1R, and GCGR.
Calling it “GLP-3” hides that pharmacological architecture.
Why Scientific Naming Matters
Nicknames are common in emerging research areas.
Some disappear. Others become so widely used that they are difficult to correct.
But terminology can influence how people understand a molecule.
Consider the difference between:
Retatrutide is GLP-3.
and:
Retatrutide is a GIP/GLP-1/glucagon receptor agonist.
The second statement immediately tells a researcher:
- which receptors are involved
- that the molecule is multi-target
- that glucagon biology is part of the mechanism
- that GIP signaling remains important.
The first does none of those things.
Good scientific terminology compresses information without changing its meaning.
“GLP-3” Also Creates Confusion With GLP Biology
There is another problem.
Because GLP stands for glucagon-like peptide, the term “GLP-3” sounds like the name of a specific endogenous peptide hormone.
That could lead readers to assume scientists discovered a new hormone called glucagon-like peptide-3.
That is not what happened.
Retatrutide is a synthetic engineered peptide.
Its three-target mechanism comes from intentional molecular design, not the discovery of a new member of the GLP hormone family.
Lilly Has Addressed the Name Directly
Lilly’s current retatrutide information specifically discusses the “GLP-3” terminology.
The company states that a more suitable description is triple agonist, reflecting retatrutide’s activity at GIP, GLP-1, and glucagon receptors.
That is useful because it removes ambiguity about how the developer itself describes the mechanism.
Lilly also continues to classify retatrutide as investigational and says it has not been approved by FDA or another regulatory agency.
Is Retatrutide a GLP-1 Drug?
There is a more nuanced version of the terminology question.
Could someone reasonably call retatrutide a GLP-1-based drug?
In a broad conversational sense, retatrutide belongs to the rapidly developing field of incretin and GLP-1-related metabolic pharmacology.
But scientifically, calling it simply a GLP-1 receptor agonist is incomplete.
It is a triple receptor agonist that includes GLP-1R activity.
Those extra receptor activities are not incidental.
They are fundamental to the molecule’s design.
Retatrutide Is Also Not Simply “Tirzepatide Plus Glucagon”
Another shortcut should be avoided as well.
Retatrutide activates the same broad receptor families as a hypothetical combination of tirzepatide’s GIP/GLP-1 activity plus glucagon receptor activity.
But retatrutide is not literally tirzepatide with glucagon added.
The two molecules have different sequences and receptor pharmacology.
Retatrutide was engineered as its own peptide with a distinct receptor-potency profile.
That matters when comparing experimental mechanisms.
Two peptides can activate the same receptor families while producing different responses because of differences in:
- potency
- efficacy
- pharmacokinetics
- receptor bias
- tissue exposure.
What Does “Triple Agonist” Actually Tell Us?
The term provides two useful pieces of information.
First, the molecule activates three receptor systems.
Second, it functions as an agonist, meaning it produces receptor signaling rather than simply binding without activation.
Retatrutide has demonstrated functional activity at all three receptors in laboratory assays.
That is different from saying it simply binds to three targets.
Functional receptor assays measure downstream effects such as cAMP signaling after receptor activation.
This distinction becomes important in pharmacology because receptor binding and receptor activation are not identical concepts.
Triple Does Not Mean Equal
The word “triple” can still be misunderstood.
It does not mean:
33% GIP + 33% GLP-1 + 33% glucagon.
Reported functional potency at the human receptors differs considerably.
The strongest potency in the original assays was observed at GIPR, followed by GLP-1R and then GCGR.
The complete biological effect depends on much more than those EC50 values, including receptor expression, drug concentration, tissue distribution, and downstream signaling.
But it demonstrates why “three receptors” should not be interpreted as “three equal receptor effects.”
What Does This Mean for Laboratory Research?
Accurate nomenclature becomes especially important when researchers are:
- comparing receptor agonists
- designing binding assays
- measuring cAMP signaling
- evaluating selectivity
- developing analytical methods
- studying multi-agonist structure-activity relationships.
A laboratory using retatrutide research material, for example, is working with a molecule defined by its specific structure and receptor profile, not a generic substance called “GLP-3.”
For experimental documentation, the preferred terms would be:
retatrutide
LY3437943
and, where mechanism is relevant:
GIPR/GLP-1R/GCGR triple agonist.
Using precise terminology makes experimental records easier to interpret and reproduce.
The Product URL Can Be Misleading Without Context
Interestingly, research suppliers and online discussions sometimes use terms such as “GLP-3” because that is what people are searching for.
That can make sense as a search or catalog reference.
But the technical description should still clarify that retatrutide is not actually a GLP-3 receptor agonist.
Search language and scientific language do not always evolve at the same pace.
The best approach is to acknowledge the popular term and then explain it correctly.
Retatrutide Is Still Investigational
Terminology also matters because public interest in the molecule has grown faster than its regulatory status.
Positive Phase 3 results have now been reported from several retatrutide trials, and Lilly has said it plans to submit a Biologics License Application to FDA in the first quarter of 2027.
But as of September 2026, retatrutide is not FDA approved.
FDA also states that retatrutide is not a component of an FDA-approved drug and cannot currently be used in compounding under federal law.
So another inaccurate shortcut would be to treat “GLP-3” as the name of a commercially approved medication class.
It is neither.
Why the Correct Terminology Will Matter More Over Time
Retatrutide may not be the last triple agonist.
Researchers are already studying additional multi-receptor peptide combinations.
As the field grows, a vague naming system based on “GLP number” would quickly become impossible to use.
Imagine trying to distinguish:
- GIP/GLP-1/glucagon agonists
- GLP-1/glucagon dual agonists
- GIP/GLP-1 dual agonists
- GLP-1/amylin combinations
- future tetra-agonists
by simply assigning higher GLP numbers.
The terminology would no longer describe the pharmacology.
Naming compounds according to their actual receptor targets scales much better as peptide engineering becomes more complex.
“Triple Agonist” Is More Than a Better Name
The phrase also highlights the most scientifically important aspect of retatrutide.
Retatrutide represents an attempt to combine several metabolic signals in one engineered peptide.
Its research value comes partly from studying how those receptor pathways interact.
Questions include:
- Does glucagon receptor activity materially increase energy expenditure in humans?
- How much does high GIPR potency contribute?
- Does receptor balance affect tolerability?
- Could a different GIPR/GLP-1R/GCGR ratio work differently?
- How does tissue receptor expression change the response?
Calling the molecule a triple agonist keeps attention on these real pharmacological questions.
Calling it GLP-3 does not.
Conclusion
Retatrutide is frequently called “GLP-3” online, but the term is scientifically inaccurate.
There is no third GLP receptor involved.
Retatrutide is a single engineered peptide that activates:
GIPR
GLP-1R
and
GCGR.
That makes it a GIP/GLP-1/glucagon triple agonist, not a GLP-3 agonist.
The difference matters because each receptor contributes distinct biology, and the interaction among those pathways is the central scientific idea behind the molecule.
“GLP-3” may remain popular shorthand.
But for research, pharmacology, and technical documentation, retatrutide and triple receptor agonist are the terms that actually describe what the molecule is.
Retatrutide remains investigational and has not yet been approved by FDA or another regulatory agency.
References
Eli Lilly and Company. What to Know About Retatrutide. Updated July 2026.
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. 2024.
Eli Lilly and Company. Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 Results. July 2026.
U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.